Ionis Pharmaceuticals Inc. (IONS) announced that the Committee for Medicinal Products for Human Use, or CHMP, of the European Medicines Agency has adopted a positive opinion recommending approval of DAWNZERA for the routine prevention of recurrent attacks of hereditary angioedema in adults and adolescents aged 12 years and older.Hereditary angioedema (HAE) is a rare, potentially life-threatening genetic condition characterized by recurrent episodes of severe swelling in various parts of the body, including ...